About S-adenosylmethionine sensor upstream of mTORC1
S-adenosylmethionine sensor upstream of mTORC1 (SAMTOR) is a protein
from Homo sapiens identified by UniProt accession
Q1RMZ1, 405 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | S-adenosylmethionine sensor upstream of mTORC1 |
|---|
| UniProt accession | Q1RMZ1 |
|---|
| Gene | SAMTOR |
|---|
| Organism | Homo sapiens |
|---|
| Length | 405 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (12)
Diseases linked to this target (Open Targets).
- body mass index · score 0.06
- fat body mass · score 0.04
- body weight · score 0.04
- body fat percentage · score 0.04
- lean body mass · score 0.03
- body height · score 0.03
- neoplasm · score 0.00
- Homocystinuria · score 0.00
- neuroblastoma · score 0.00
- cancer · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q1RMZ1-F1 | alphafold | PREDICTED | 79.26 | — |
Amino-acid sequence (405 residues)
MEPGAGGRNT ARAQRAGSPN TPPPREQERK LEQEKLSGVV KSVHRRLRKK YREVGDFDKI WREHCEDEET LCEYAVAMKN LADNHWAKTC EGEGRIEWCC SVCREYFQNG GKRKALEKDE KRAVLATKTT PALNMHESSQ LEGHLTNLSF TNPEFITELL QASGKIRLLD VGSCFNPFLK FEEFLTVGID IVPAVESVYK CDFLNLQLQQ PLQLAQDAID AFLKQLKNPI DSLPGELFHV VVFSLLLSYF PSPYQRWICC KKAHELLVLN GLLLIITPDS SHQNRHAMMM KSWKIAIESL GFKRFKYSKF SHMHLMAFRK ISLKTTSDLV SRNYPGMLYI PQDFNSIEDE EYSNPSCYVR SDIEDEQLAY GFTELPDAPY DSDSGESQAS SIPFYELEDP ILLLS
Explore S-adenosylmethionine sensor upstream of mTORC1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets